drugset / Trial / NCT04203498

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

NCT04203498

Phase 3 Terminated 139 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).

Timeline

Start
2020-10-01
Primary completion
2023-02-10
Completion
2023-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Nabiximols Other / unclassified Other

Indications